Basics Prelude Therapeutics Inc. IPO Date: September 25, 2020 Sector: Healthcare Industry: Biotech Market Cap: $69.62M Activated in VL: True Average Daily Range Avg Daily Range: $0.58 | 4.31% Avg Daily Range (30 D): $0.05 | 5.46% Avg Daily Range (90 D): $0.05 | 4.82% Institutional Daily Volume Avg Daily Volume: .17M Avg Daily Volume (30 D): .13M Avg Daily Volume (90 D): .1M Trade Size Avg Trade Size (Sh.): 102 Avg Trade Size (Sh.) (30 D): 187 Avg Trade Size (Sh.) (90 D): 186 Institutional Trades Total Inst.Trades: 333 Avg Inst. Trade: $1.98M Avg Inst. Trade (30 D): $.81M Avg Inst. Trade (90 D): $.81M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.36M Avg Closing Trade (30 D): $.81M Avg Closing Trade (90 D): $.81M Avg Closing Volume: 87.02K     News Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai Sep 13, 2024 @ 2:00 PM Prelude Therapeutics’ SMARCA2 Degrader PRT3... Source: Prelude Therapeutics Incorporated Jun 3, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Upcoming He... Source: Prelude Therapeutics, Inc. May 9, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Citizens JM... Source: Prelude Therapeutics, Inc. May 7, 2024 @ 11:01 AM Prelude Therapeutics Reports First Quarter 2024 Fi... Source: Prelude Therapeutics, Inc. Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.64 $-.41 $-.42 Diluted EPS $-1.64 $-.41 $-.42 Revenue $ 7M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -124.32M $ -31.23M $ -32.09M Operating Income / Loss $ -135.01M $ -32.19M $ -34.61M Cost of Revenue $ $ $ Net Cash Flow $ -2.08M $ -14.52M $ 27.8M PE Ratio